Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Prevention of Transmission of Hiv, Hepatitis B Virus, Hepatitis C Virus, and Tuberculosis in Prisoners Publisher Pubmed



Kamarulzaman A1, 2 ; Reid SE3, 4 ; Schwitters A5 ; Wiessing L6 ; Elbassel N7 ; Dolan K8 ; Moazen B9, 10 ; Wirtz AL11 ; Verster A5 ; Altice FL1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Centre of Excellence for Research in AIDS, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia
  2. 2. Yale School of Medicine, New Haven, CT, United States
  3. 3. Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
  4. 4. University of Alabama at Birmingham, Birmingham, AL, United States
  5. 5. Department of HIV/AIDS, WHO, Geneva, Switzerland
  6. 6. European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal
  7. 7. Columbia University School of Social Work, New York, NY, United States
  8. 8. National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
  9. 9. Non-Communicable Diseases Research Centre, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  10. 10. Institute of Public Health, University of Heidelberg, Heidelberg, Germany
  11. 11. Center for Public Health and Human Rights, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States

Source: The Lancet Published:2016


Abstract

The prevalence of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis are higher in prisons than in the general population in most countries worldwide. Prisons have emerged as a risk environment for these infections to be further concentrated, amplified, and then transmitted to the community after prisoners are released. In the absence of alternatives to incarceration, prisons and detention facilities could be leveraged to promote primary and secondary prevention strategies for these infections to improve prisoners health and reduce risk throughout incarceration and on release. Effective treatment of opioid use disorders with opioid agonist therapies (eg, methadone and buprenorphine) prevents blood-borne infections via reductions in injection in prison and after release. However, large gaps exist in the implementation of these strategies across all regions. Collaboration between the criminal justice and public health systems will be required for successful implementation of these strategies. © 2016 Elsevier Ltd
Related Docs
View other Related Docs
1. Prevalence of Drug Injection, Sexual Activity, Tattooing, and Piercing Among Prison Inmates, Epidemiologic Reviews (2018)
2. Global Burden of Hiv, Viral Hepatitis, and Tuberculosis in Prisoners and Detainees, The Lancet (2016)
3. Comparison of Tuberculosis Indicators After Implementation of the Clinical Protocol for Tuberculosis and Hiv Management in Iranian Prisons: A Quasi-Experimental Study, Journal of Health Research (2020)
4. Prevalence and Associated Factors of Hiv Infection Among Male Prisoners in Tehran, Iran, Archives of Iranian Medicine (2017)
5. Methadone Maintenance Treatment Program in Prisons From the Perspective of Medical and Non-Medical Prison Staff: A Qualitative Study in Iran, International Journal of Health Policy and Management (2015)
6. Continuum of Hepatitis C Care Cascade in Prison and Following Release in the Direct-Acting Antivirals Era, Harm Reduction Journal (2020)
7. Substance Use and Hiv Among Female Sex Workers and Female Prisoners: Risk Environments and Implications for Prevention, Treatment, and Policies, Journal of Acquired Immune Deficiency Syndromes (2015)
8. Global Patterns of Opioid Use and Dependence: Harms to Populations, Interventions, and Future Action, The Lancet (2019)
Experts (# of related papers)
View all Related Experts
Seyed Ahmad Seyed Alinaghi (12)
Mostafa Hosseini (6)
Other Related Docs
9. Patterns of Drug Use and Related Factors Among Prisoners in Iran: Results From the National Survey in 2015, Journal of Primary Prevention (2020)
10. People Who Inject Drugs in Prison: Hiv Prevalence, Transmission and Prevention, International Journal of Drug Policy (2015)
11. Revision and Implementation of “Clinical Guideline for Tuberculosis and Hiv in Prisons”, Great Tehran Prison, Iran, Infectious Disorders - Drug Targets (2018)
12. Prevalence of Sexually Transmitted Infections and Associated Risk Behaviors in Prisoners: A Systematic Review, Health Science Reports (2022)
13. Comparison of Hiv Indicators After the Implementation of a New Model for Tb and Hiv Management in an Iranian Prison, Infectious Disorders - Drug Targets (2020)
14. A Follow-Up Program After Prison Release for Hiv-Positive Patients, Asian Pacific Journal of Tropical Disease (2015)
15. Comparing Tuberculosis Incidence in a Prison With the Society, Tehran, Iran, Archives of Clinical Infectious Diseases (2018)
16. Prevalence of Tuberculosis in a Prison in Tehran by Active Case Finding, Infectious Disorders - Drug Targets (2019)
17. Epidemiology of Hiv in Iran, Current HIV Research (2020)
18. Hiv-Related Risk Behaviors Among Male Inmates of Tehran, Iran, Asian Pacific Journal of Tropical Disease (2016)
19. Hiv in Iran: Onset, Responses, and Future Directions, AIDS (2021)
20. Hiv Prevalence and Continuum of Care Among Incarcerated People in Iran From 2010 to 2017, Harm Reduction Journal (2022)
21. Predictors of Tuberculosis in Hiv/Aids Patients Referred to Behavioral Diseases Consultation Center: A Registry-Based Study in Abadan, Southwest of Iran, Shiraz E Medical Journal (2016)
22. Availability, Accessibility, and Coverage of Needle and Syringe Programs in Prisons in the European Union, Epidemiologic Reviews (2020)
23. Hiv Prevalence and Correlations in Prisons in Different Regions of the World: A Review Article, Open AIDS Journal (2018)
24. Covid-19 Pandemic and Physical Exercise: Lessons Learnt for Confined Communities, Frontiers in Psychology (2021)